Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncologyi. (Source: GSK news)
Source: GSK news - April 1, 2014 Category: Pharmaceuticals Source Type: news

Hyponatremia Associated with Poorer Overall Survival
In metastatic renal cell cancer (mRCC) patients treated with targeted therapy, baseline hyponatremia is associated with poorer overall survival (OS), time to treatment failure (TTF), and disease control rate (DCR), according to a study published in European Urology.03/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 29, 2014 Category: Cancer & Oncology Source Type: news

Court bans export of generic kidney, liver cancer medication
Sorafenat is the generic alternative to Bayer's Nexavar, and is used to treat a type of kidney cancer called advanced renal cell carcinoma as well as liver cancer.03/28/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 28, 2014 Category: Cancer & Oncology Source Type: news

Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma
Raman molecular imaging was evaluated as a tool for differentiating between kidney tumors which are sometimes confused using conventional histopathological methods.03/18/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 18, 2014 Category: Cancer & Oncology Source Type: news

Tyrosine kinase inhibitor sorafenib decreases (111)In-girentuximab uptake in patients with clear cell renal cell carcinoma
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC).03/14/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 14, 2014 Category: Cancer & Oncology Source Type: news

Differentiation of Oncocytoma From Chromophobe RCCDifferentiation of Oncocytoma From Chromophobe RCC
Newly described biomarkers may increase the ability to differentiate benign renal oncocytoma from other renal cell carcinomas with a greater chance of metastasis. Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Axitinib – Treatment for Advanced Renal Cell Carcinoma
Inlyta (axitinib) was developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 5, 2014 Category: Pharmaceuticals Source Type: news

Neurologic status at surgery affects metastatic spinal renal cell carcinoma survival
Neurological status at surgery, the grade of the original nephrectomy specimen and activity of the systemic disease were factors found to influence a patient’s survival after spine surgery for metastatic spinal renal cell carcinoma...02/28/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 28, 2014 Category: Cancer & Oncology Source Type: news

Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy
The survival and prognosis of mRCC patients may thus be significantly improved with the suitable use of newer targeted agents.02/26/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 26, 2014 Category: Cancer & Oncology Source Type: news

Cancer Genetics (CGIX) to Present Positive Data from UroGenRA-Kidney Test
Cancer Genetics, Inc. (Nasdaq: CGIX) announced that new data that further validates its UroGenRA-Kidney diagnostic test for renal cell cancer...02/25/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 25, 2014 Category: Cancer & Oncology Source Type: news

Perioperative blood transfusion worsens kidney cancer patients’ survival
Patients who receive blood transfusions around the time of their surgery for nonmetastatic renal cell carcinoma have a worse chance of survival than those who do not, results of a large US study suggest. (Source: MedWire News - Urology)
Source: MedWire News - Urology - February 24, 2014 Category: Urology & Nephrology Source Type: news

Perioperative blood transfusion worsens kidney cancer patients’ survival
Patients who receive blood transfusions around the time of their surgery for nonmetastatic renal cell carcinoma have a worse chance of survival than those who do not, results of a large US study suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 24, 2014 Category: Cancer & Oncology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.02/23/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 23, 2014 Category: Cancer & Oncology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. (Source: MedWire News - Urology)
Source: MedWire News - Urology - February 21, 2014 Category: Urology & Nephrology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 21, 2014 Category: Cancer & Oncology Source Type: news

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies
To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US.02/20/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2014 Category: Cancer & Oncology Source Type: news

Clin Onc News Report: Options in Multiple Myeloma, Renal Cell Carcinoma
(MedPage Today) -- A regular update on what's new in cancer research from our friends at Clinical Oncology News. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 18, 2014 Category: Hematology Source Type: news

Sunitinib safe, effective in patients with mRCC, renal insufficiency
Sunitinib demonstrated encouraging activity and manageable toxicities in patients with metastatic renal cell carcinoma and renal insufficiency, according to study results.02/14/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 14, 2014 Category: Cancer & Oncology Source Type: news

Vitreous Hemorrhage as the Initial Sign of Renal Cell Carcinoma Metastasis
Choroidal metastases generally appear as a solitary, yellow- or orange-colored mass in the macula or perimacular region of the eye. In an analysis of 520 eyes with uveal metastasis, the tumor appeared as a solitary mass (71%) with mean basal dimension of 9 mm and mean thickness of 3 mm.1 In that analysis, associated findings included subretinal fluid (73%) and retinal pigment epithelial alterations (57%). Hemorrhage is an unusual finding with choroidal metastatic disease. Single case reports have highlighted this rare association.02/11/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 11, 2014 Category: Cancer & Oncology Source Type: news

Survival Outcomes Similar Regardless of Sorafenib-Sunitinib Sequence in mRCC
The SWITCH trial makes it official: it makes no difference whether patients with metastatic renal cell carcinoma (mRCC) first start on sorafenib and then switch to sunitinib upon progression or vice versa.02/10/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 10, 2014 Category: Cancer & Oncology Source Type: news

Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management
Purpose Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary. No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer.02/09/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 9, 2014 Category: Cancer & Oncology Source Type: news

Journal of the National Cancer Institute: Investigation of the Obesity Paradox in RCC
Obesity increases risk for clear-cell renal cell carcinoma, but obese patients appear to experience longer survival than nonobese patients. Why the paradox?02/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 7, 2014 Category: Cancer & Oncology Source Type: news

A Road Map for Success in RCC
SAN FRANCISCO (MedPage Today) -- Renal cell carcinoma had a mix of highs and lows over the past decade, and shifting the balance to the high side requires more emphasis on molecular biology and genetics, a clinician and investigator said here. (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 5, 2014 Category: Surgery Source Type: news

Two Strategies Lead to Similar Survival in RCC
SAN FRANCISCO (MedPage Today) -- Sequential targeted therapy for metastatic renal cell carcinoma led to similar survival, regardless of which agent was used first, according to the first randomized study of the issue. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - February 3, 2014 Category: Urology & Nephrology Source Type: news

MET variant as a prognostic marker in clear cell renal cell carcinoma
Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA02/02/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 2, 2014 Category: Cancer & Oncology Source Type: news

Results of the MARS study in renal cell carcinoma
Dr Vincent Launay-Vacher - Pitie-Salpetriere Hospital, Paris, France02/02/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 2, 2014 Category: Cancer & Oncology Source Type: news

2014 ASCO GU Renal Cell Cancer Abstracts
Meeting abstracts--search free!01/31/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 31, 2014 Category: Cancer & Oncology Source Type: news

Randomized Controlled Trial of Expressive Writing for Patients With Renal Cell Carcinoma
This randomized controlled trial examined the quality-of-life benefits of an expressive writing (EW) intervention for patients with renal cell carcinoma (RCC) and identified a potential underlying mechanism of intervention efficacy.01/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 30, 2014 Category: Cancer & Oncology Source Type: news

Argos Therapeutics To Present Progress Update On Adapt Phase 3 Trial With AGS-003 At 2014 Genitourinary Cancers Symposium
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will present a trial-in-progress update on the company's ongoing pivotal phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC).01/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2014 Category: Cancer & Oncology Source Type: news

FDG-PET as a predictive biomarker
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression.01/28/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 28, 2014 Category: Cancer & Oncology Source Type: news

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
DNA aptamers represent a novel strategy in anti-cancer medicine.01/22/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 22, 2014 Category: Cancer & Oncology Source Type: news

Biomarkers of renal cell carcinoma
The incidence of renal cell carcinoma (RCC) has increased steadily in past few decades and is partially attributable to the increased utilization of cross-sectional imaging.01/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 21, 2014 Category: Cancer & Oncology Source Type: news

Kidney cancer before age 47 implies hereditary cause
The diagnosis of renal cell cancer in a patient aged 46 or younger should prompt a referral for germline mutation testing and genetic counseling, according to a report published online in the Journal of Clinical Oncology.01/19/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 19, 2014 Category: Cancer & Oncology Source Type: news

Pathological characteristics and prognostic effect of peritumoral capsule penetration in renal cell carcinoma after tumor enucleation
To evaluate the pathological characteristics of peritumoral capsule (PC) and the prognostic effect of capsule penetration on tumor recurrence in patients treated with tumor enucleation for clinically intracapsular renal cell carcinomas (RCCs).01/18/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 18, 2014 Category: Cancer & Oncology Source Type: news

Obesity associated with tumor indolence in renal cell carcinoma
Obese patients with renal cell carcinoma tended to have more indolent tumors than normal-weight patients, according to study results.01/17/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 17, 2014 Category: Cancer & Oncology Source Type: news

Rexahn begins Phase IIa trial of renal carcinoma drug Archexin
US-based clinical stage biopharmaceutical firm Rexahn Pharmaceuticals has started a multi-centre Phase IIa clinical proof-of-concept trial to evaluate the safety and efficacy of Archexin in patients with metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - January 16, 2014 Category: Pharmaceuticals Source Type: news

Patient Resource Cancer Guide: Renal Cell Carcinoma
Click to download and read the PDF now: Prefer to have it in print?  Click here to order online.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Cancer & Oncology Source Type: news

Patient Resource Cancer Guide: Renal Cell Carcinoma
Click to download and read the PDF now: Prefer to have it in print?  Click here to order online.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Urology & Nephrology Source Type: news

Patient Resource Cancer Guide: Renal Cell Carcinoma
Click to download and read the PDF now: Prefer to have it in print? Click here to order online.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Urology & Nephrology Source Type: news

Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with Metastatic Renal Cell Carcinoma
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication.01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Cancer & Oncology Source Type: news

Rexahn Initiates Phase IIa Clinical Trial of Archexin ® in Patients with Metastatic Renal Cell Carcinoma
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin ® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication. 01/15/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2014 Category: Urology & Nephrology Source Type: news

Rexahn initiates Phase Ib clinical trial of RX-3117 for treatment of solid tumors
RX-3117 has broad spectrum anti-tumor activity against 80 different human cancer cell lines (including NSCLC, breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 12 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.01/10/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 10, 2014 Category: Cancer & Oncology Source Type: news

Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma
Renal cell carcinoma (RCC) frequently metastasizes to the spine, and the prognosis can be quite variable.01/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 7, 2014 Category: Cancer & Oncology Source Type: news

NewLink Genetics initiates Phase I renal cell cancer trial
NewLink Genetics Corporation, a biopharmaceutical company, has initiated a first in human Phase I clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer.01/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 7, 2014 Category: Cancer & Oncology Source Type: news

Newlink genetics launches phase i clinical trial
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer.12/20/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2013 Category: Cancer & Oncology Source Type: news

Merck, Glaxo to Partner on Renal Cell Cancer Treatment
Merck is looking for more collaborations like the one with Glaxo to test how MK-3475 works with other anticancer treatments against a variety of tumor types...12/19/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 19, 2013 Category: Cancer & Oncology Source Type: news

Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7...
Source: Merck.com - Research and Development News - December 18, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Chromophobe renal cell carcinoma with concomitant sarcomatoid transformation
Chromophobe renal cell carcinoma is the third most common form of adult renal epithelial neoplasm. A sarcomatoid component occurs in approximately 8% of all chromophobe renal cell carcinoma cases, while metaplastic bone formation is extremely rare.12/14/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2013 Category: Cancer & Oncology Source Type: news

Findings on Carcinomas Reported by Investigators at University of Texas
"We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma. In this randomised, double-blind, multicentre, phase 2 study, patients were enrolled from 49 hospitals and outpatient clinics in the Czech Republic, Germany, Japan, Russia, Spain, and USA. Patients with treatment-naive metastatic renal-cell carcinoma received axitinib 5 mg twice daily during a 4 week lead-in period..."12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news

First-Line Inlyta Active in Metastatic Kidney Cancer
First-line therapy with Inlyta® (axitinib) demonstrated clinical activity in metastatic renal cell carcinoma, according to the results of a study published in The Lancet Oncology.12/12/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2013 Category: Cancer & Oncology Source Type: news